5 Gene Editing Stocks With the Best Long-Term Potential

Page 1 of 5

In this article, we will take a look at the 5 gene editing stocks with the best long-term potential. To see more such companies, go directly to 12 Gene Editing Stocks With the Best Long-Term Potential.

5. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Number of Hedge Fund Holders: 38

Massachusetts-based Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has several treatments in its pipeline based on gene therapies. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in 2021 also entered into a deal with Beam Therapeutics to create new gene editing treatments.

A total of 38 hedge funds in Insider Monkey’s database of 943 hedge funds were bullish on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). The biggest hedge fund stakeholder of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was Kurt Von Emster’s VenBio Select Advisor which owns a $549 million stake.

Page 1 of 5